# High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

> **NCT00283556** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kentuckiana Cancer Institute** · enrollment: 30 (estimated)

## Conditions studied

- Malignant Glioma

## Interventions

- **DRUG:** Irinotecan (Camptosar, CPT-11)

## Key facts

- **NCT ID:** NCT00283556
- **Lead sponsor:** Kentuckiana Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2010-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283556, "High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00283556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*